Work

1391P Phase III confirmatory efficacy and safety study of proposed bevacizumab biosimilar (MYL-1402O) compared with avastin, in the first-line treatment of patients with stage IV non-squamous non-small cell lung cancer (nsNSCLC)

Year: 2020

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2020.08.1705

Authors: M.A. Socinski, C. Waller, T. Idris, I. Bondarenko, A. Luft, K. Beckmann, A. Vishweswaramurthy, S. Loganathan, G. Ranganna, A. Barve

Institutions: AdventHealth, University of Freiburg, University Medical Center Freiburg, Regional Clinical Hospital named after II Mechnikov, Leningrad Regional Cancer Center, Mylan (Germany), Biocon (India), Mylan (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3088585516

FWCI: 0.141

Cites:

Cited by: 2

Related to: 10